Australia’s Government Launches Review of Clinical Laboratory Testing Fees
Sonic Healthcare stock slides on announcement of Medicare Australia funding changes
In Australia, funding for pathology services and clinical laboratory testing is now undergoing review by the government health service. Last month, when news broke that the Australian Department of Health and Ageing was initiating a review of pathology funding, there was an immediate response by the stock market, as reflected in the lower price for shares of Sonic Healthcare, Ltd. (ASX:SHL), Australia’s largest provider of pathology services and clinical lab testing.